Form 10 Explorer
10-Q
Quarterly Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Jun 30, 2025

Fiscal Year: 2025

View on EDGAR
Balance Sheet
31 line items · 2 periods
XBRL
ItemJun 30, 2025Dec 31, 2024
ASSETS
Current assets:
Cash and Cash Equivalents
6,492,6568,641,622
Other Non-Operating Current Assets
195,903566,278
Total current assets
6,688,5599,207,900
Other Non-Operating Non-Current Assets
280,342110,548
Total assets
6,968,9019,318,448
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
3,171,0151,921,189
Other Non-Operating Current Liabilities
4,570,6315,921,908
Other Current Liabilities
1,388,118888,449
Other Non-Operating Current Liabilities
70,95770,957
UIC License Agreement
70,95770,957
Total current liabilities
9,200,7218,802,503
Long term liabilities:
Accrued interest, less current portion
16,8936,768
UIC License Agreement
16,8936,768
License payable
404,991404,991
Total long-term liabilities
421,884411,759
Total liabilities
9,622,6059,214,262
Stockholders’ equity (deficit):
Preferred Stock
00
Total Stockholders' Equity
2020
Total Stockholders' Equity
141,992,554132,484,015
Total Stockholders' Equity
(144,646,278)(132,379,849)
Total stockholders’ equity (deficit)
(2,653,704)104,186
Common Stock
2020
Additional Paid-in Capital
141,992,554132,484,015
Retained Earnings
(144,646,278)(132,379,849)
Total liabilities and stockholders’ equity (deficit)
6,968,9019,318,448